Arrowhead submits FDA application for hep B treatment

Arrowhead Research Corporation, a biopharmaceutical company specializing in creating targeted RNAi therapies, recently submitted an application to the U.S. Food and Drug Administration (FDA) for further testing of a new drug, called ARC-520, to treat chronic hepatitis B virus infection.

Arrowhead is seeking authorization to begin Phase 2b randomized double-blind placebo-controlled multi-dose studies in multiple locations. The studies will determine how much reduction of hepatitis B surface antigens will occur after doses of ARC-520, entecavir and tenofovir. Scientists also want to determine the safety of the treatments.

Researchers will use pharmacodynamic objectives and exploratory safety to uncover results. They will also implement a placebo to learn the efficacy of the HBV infection.

Subjects will include patients who test negative for hepatitis B e-antigen (HBeAg) as well as others who test positive for HBeAg.

The FDA application “represents achievement of a key 2014 goal,” Dr. Christopher Arnzalon, CEO and president of Arrowhead Research Corporation, said. “We look forward to beginning multi-dose studies with ARC-520.”

Arrowhead announced that it plans to submit similar applications to gain approval for clinical trials in its other jurisdictions, including Asia and Europe.

Organizations in this Story

PharmiWeb U.S. Food and Drug Administration (FDA)

Want to get notified whenever we write about any of these organizations ?
Next time we write about any of these organizations, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.